Search results
Seven things everyone should know about retina specialists
San Francisco Chronicle· 6 days agoWhen retinal disease strikes and a clear view of the world is replaced by a curtain-like shadow, central blurriness or straight lines that appear wavy, it’s critical to seek out the expert care ...
FDA Roundup: April 26, 2024
FOX21 Colorado Springs· 6 days agoThis represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions. Full prescribing ...
Belite Bio secures $25 million in registered direct offering By Investing.com
Investing.com· 7 days agoBelite Bio, Inc (NASDAQ: BLTE), a biopharmaceutical company specializing in degenerative retinal...
Oculis (NASDAQ:OCS) Price Target Cut to $28.00
ETF DAILY NEWS· 7 days agoOculis (NASDAQ:OCS – Get Free Report) had its price target dropped by research analysts at HC Wainwright from $29.00 to $28.00 in a research note issued to investors on Wednesday, Benzinga reports ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoIn time for Vision Health Month this May, the Canadian Ophthalmological Society, the national authority on eye and vision care in Canada, has released a new survey to assess Canadians' awareness ...
Sigma Planning Corp Reduces Stake in REGENXBIO Inc. (NASDAQ:RGNX)
ETF DAILY NEWS· 4 days agoSigma Planning Corp lowered its position in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 63.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities ...
Apellis Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:APLS)
ETF DAILY NEWS· 2 days agoApellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the recipient of some unusual options trading activity on Tuesday. In related news, insider Adam J. Townsend sold 1,148 shares ...
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3.5% on Analyst Downgrade
ETF DAILY NEWS· 2 days agoApellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) dropped 3.5% during mid-day trading on Monday after Mizuho lowered their price target on the stock from $60.00 to $52.00. Apellis ...
SightMD Pennsylvania Expands Practice with Acquisition of James Lewis, MD
PRWeb· 4 days ago/PRNewswire-PRWeb/ -- SightMD Pennsylvania, a leading multi-specialty ophthalmology platform, is pleased to announce the acquisition of James Lewis, MD....
Australian project to 'print' a fix for faulty eye and brain cells
Cosmos· 4 days ago“Imagine a world that we could simply ‘print’ neurological diseases out of existence using bio inks and cheap desktop printers.” Well hello future, or at least one that Matthew Griffith, a biophysicist ...
